Metastases in bones, lymph nodes and lungs are common challenges among oncology patients (e.g. breast cancer, prostate cancer, osteosarcoma) and are the primary cause of death. Efficacious new treatment options are sorely needed. Alpha-particle emitting radionuclides being highly cytotoxic may fulfil this critical need. We study a novel technology with potentially broad therapeutic applications for cancer micrometastases by means of dual targeted alpha particle radiation. The treatment involves administration of a bone-seeking, alpha-particle emitting radionuclide 224Ra and its daughter radionuclide 212Pb solution containing chelator-labelled new and existing molecular ligands and tumour-associated monoclonal antibodies (mAb) as carriers for the daughter radionuclide. Pb-212 is a source of highly cytotoxic alpha particles via its decay to 212Bi daughter.
Contact information Asta Juzeniene, Scientist, Ph.D. Department of Radiation Biology, Institute for Cancer Research The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway Tel. +47 22 78 12 00, Fax +47 22 78 12 07
Stenberg VY, Juzeniene A, Chen Q, Yang X, Bruland ØS, Larsen RH(2020) Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212 Pb]Pb-NG001 for prostate cancer J Labelled Comp Radiopharm DOI 10.1002/jlcr.3825, PubMed 31919866
Grigalavicius M, Mastrangelopoulou M, Berg K, Arous D, Ménard M, Raabe-Henriksen T, Brondz E, Siem S, Görgen A, Edin NFJ, Malinen E, Theodossiou TA(2019) Proton-dynamic therapy following photosensitiser activation by accelerated protons demonstrated through fluorescence and singlet oxygen production Nat Commun, 10(1), 3986 DOI 10.1038/s41467-019-12042-7, PubMed 31484929
Theodossiou TA, Ali M, Grigalavicius M, Grallert B, Dillard P, Schink KO, Olsen CE, Wälchli S, Inderberg EM, Kubin A, Peng Q, Berg K(2019) Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy NPJ Breast Cancer, 5, 13 DOI 10.1038/s41523-019-0108-8, PubMed 30993194